Tax Inversions and Price Attacks: Will Wyden Make the Link?
This article was originally published in RPM Report
Finance Committee Chair Ron Wyden is promising immediate action to stop the trend of biopharma companies acquiring ex-US firms to reincorporate for tax reasons. The prospects for legislation are limited – but will the debate open up a new angle to attack biopharma pricing in the US?
You may also be interested in...
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.